Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 83 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Opioid-Induced Constipation (OIC) - Pipeline Review, H1 2015', provides an overview of the Opioid-Induced Constipation (OIC)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Opioid-Induced Constipation (OIC), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opioid-Induced Constipation (OIC) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Opioid-Induced Constipation (OIC)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Opioid-Induced Constipation (OIC) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Opioid-Induced Constipation (OIC) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Opioid-Induced Constipation (OIC) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons To Buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Opioid-Induced Constipation (OIC)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Opioid-Induced Constipation (OIC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Opioid-Induced Constipation (OIC) Overview 7
Therapeutics Development 8
Pipeline Products for Opioid-Induced Constipation (OIC) - Overview 8
Pipeline Products for Opioid-Induced Constipation (OIC) - Comparative Analysis 9
Opioid-Induced Constipation (OIC) - Therapeutics under Development by Companies 10
Opioid-Induced Constipation (OIC) - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Opioid-Induced Constipation (OIC) - Products under Development by Companies 14
Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development 15
AstraZeneca PLC 15
Cosmo Pharmaceuticals S.p.A 16
Cubist Pharmaceuticals, Inc. 17
Develco Pharma Schweiz AG 18
Ironwood Pharmaceuticals, Inc. 19
S.L.A. Pharma AG 20
Salix Pharmaceuticals Ltd. 21
Shionogi & Co., Ltd. 22
Sucampo Pharmaceuticals, Inc. 23
Synergy Pharmaceuticals, Inc. 24
Opioid-Induced Constipation (OIC) - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
axelopran - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
bevenopran - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
linaclotide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
lubiprostone - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
methylnaltrexone bromide - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
naldemedine - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
naloxegol oxalate - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
naloxone hydrochloride - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
naloxone hydrochloride PR - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
naloxone hydrochloride SR - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
SP-333 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Opioid-Induced Constipation (OIC) - Recent Pipeline Updates 53
Opioid-Induced Constipation (OIC) - Dormant Projects 72
Opioid-Induced Constipation (OIC) - Discontinued Products 73
Opioid-Induced Constipation (OIC) - Product Development Milestones 74
Featured News & Press Releases 74
Dec 30, 2014: Sucampo Announces Acceptance of New Drug Submission for AMITIZA (lubiprostone) by Health Canada 74
Dec 09, 2014: MOVENTIG approved in the European Union for opioid-induced constipation 74
Nov 19, 2014: Synergy Pharmaceuticals Announces Positive Results of SP-333 Phase 2 Trial in Patients with Opioid-Induced Constipation 75
Oct 16, 2014: Ironwood Pharmaceuticals Announces Initiation of Phase II Trial of Linaclotide in Adult Patients with Opioid-Induced Constipation 76
Oct 13, 2014: Clinical Data for AMITIZA Lubiprostone to be Presented at the American College of Gastroenterology 2014 Annual Scientific Meeting 77
Oct 06, 2014: Progenics Receives $40 Million Milestone Following FDA Approval of RELISTOR for OIC Patients With Chronic Non-Cancer Pain 77
Sep 29, 2014: Sucampo and Takeda Launch Direct-to-Consumer Advertising Campaign for AMITIZA (lubiprostone) for Chronic Idiopathic Constipation 78
Sep 29, 2014: FDA Approves RELISTOR Subcutaneous Injection for the Treatment of Opioid-Induced Constipation in Patients with Chronic Non-cancer Pain 79
Sep 26, 2014: MOVENTIG (naloxegol) receives positive CHMP opinion in the EU for the treatment of adults with opioid-induced constipation 80
Sep 16, 2014: FDA Approves MOVANTIK (naloxegol) Tablets C-II for the Treatment of Opioid-Induced Constipation in Adult Patients with Chronic Non-Cancer Pain 81
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 83
Disclaimer 83

List of Tables
Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2015 8
Number of Products under Development for Opioid-Induced Constipation (OIC) - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Opioid-Induced Constipation (OIC) - Pipeline by AstraZeneca PLC, H1 2015 15
Opioid-Induced Constipation (OIC) - Pipeline by Cosmo Pharmaceuticals S.p.A, H1 2015 16
Opioid-Induced Constipation (OIC) - Pipeline by Cubist Pharmaceuticals, Inc., H1 2015 17
Opioid-Induced Constipation (OIC) - Pipeline by Develco Pharma Schweiz AG, H1 2015 18
Opioid-Induced Constipation (OIC) - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 19
Opioid-Induced Constipation (OIC) - Pipeline by S.L.A. Pharma AG, H1 2015 20
Opioid-Induced Constipation (OIC) - Pipeline by Salix Pharmaceuticals Ltd., H1 2015 21
Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co., Ltd., H1 2015 22
Opioid-Induced Constipation (OIC) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2015 23
Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals, Inc., H1 2015 24
Assessment by Monotherapy Products, H1 2015 25
Number of Products by Stage and Target, H1 2015 27
Number of Products by Stage and Mechanism of Action, H1 2015 29
Number of Products by Stage and Route of Administration, H1 2015 31
Number of Products by Stage and Molecule Type, H1 2015 33
Opioid-Induced Constipation (OIC) Therapeutics - Recent Pipeline Updates, H1 2015 53
Opioid-Induced Constipation (OIC) - Dormant Projects, H1 2015 72
Opioid-Induced Constipation (OIC) - Discontinued Products, H1 2015 73